BRIEF published on 08/14/2025 at 07:05, 11 months 21 days ago Relief Therapeutics Releases 2025 Half-Year Report Relief Therapeutics RLF-TD011 RLF-OD032 2025 Half-Year Report NeuroX Partnership
PRESS RELEASE published on 08/14/2025 at 07:00, 11 months 21 days ago Relief Therapeutics Publishes 2025 Half-Year Report Relief Therapeutics published its 2025 half-year report, highlighting progress in pipeline candidates for rare diseases and financial status. Corporate update includes advances in wound care and liquid formulation for phenylketonuria Financial Status Relief Therapeutics Rare Diseases 2025 Half-Year Report Pipeline Candidates
BRIEF published on 08/11/2025 at 07:05, 11 months 24 days ago Relief Therapeutics Advances 2025 Half-Year Report Publication Biopharmaceutical Company Relief Therapeutics Innovative Treatments Geneva Half-Year Report 2025
PRESS RELEASE published on 08/11/2025 at 07:00, 11 months 24 days ago Relief Therapeutics Advances Publication of 2025 Half-Year Report Relief Therapeutics advances publication of its 2025 half-year report from August 27 to August 14, 2025, indicating completion ahead of schedule. Company to provide shareholder update and financial statements Biopharmaceutical Relief Therapeutics Publication Innovative Treatment Options 2025 Half-Year Report
BRIEF published on 07/29/2025 at 07:05, 1 year ago Relief Therapeutics and NeuroX to Merge, Expanding AI Health Tech SIX Swiss Exchange Mergers & Acquisitions Neurological Diseases AI Health Tech MindMaze
PRESS RELEASE published on 07/29/2025 at 07:00, 1 year ago Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze Relief Therapeutics to merge with NeuroX, successor to MindMaze, creating a SIX-listed, AI-driven health tech company. Transaction expected to close in Q4 2025 Business Combination Relief Therapeutics MindMaze NeuroX AI-driven Health Tech
BRIEF published on 06/20/2025 at 07:05, 1 year 1 month ago Relief Therapeutics Faces FDA Setback for RLF-TD011 QIDP Designation RLF-TD011 Orphan Drug FDA Response Epidermolysis Bullosa QIDP Designation
PRESS RELEASE published on 06/20/2025 at 07:00, 1 year 1 month ago Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 Relief Therapeutics receives FDA response on QIDP request for RLF-TD011, impacting EB treatment strategy with Orphan Drug and Rare Pediatric Disease designations Relief Therapeutics RLF-TD011 FDA Response Epidermolysis Bullosa QIDP Request
BRIEF published on 06/12/2025 at 11:05, 1 year 1 month ago Relief Therapeutics Announces Results of Annual General Meeting Financial Statements Shareholder Approval Annual Meeting Board Elections Compensation Approval
PRESS RELEASE published on 06/12/2025 at 11:00, 1 year 1 month ago Relief Therapeutics Announces Results of Annual General Meeting Relief Therapeutics announces results of its Annual General Meeting with shareholders approving all proposals by a large majority. AGM covers key agenda items and re-election of board members and auditors Board Of Directors Annual General Meeting Shareholders Relief Therapeutics AGM Results
Published on 08/04/2026 at 09:10, 2 hours 16 minutes ago HM Exploration Drills 18.45 Metres of 1.14% Cu, 2.42 % Zn, 16.74 g/t Ag and 0.32 g/t Au in Upper Lens; 5.42m of 1.99% Cu, 1.66% Zn, 15.39g/t Ag and 0.8g/t Au in Lower lens at Lewis Pilley's
Published on 08/04/2026 at 09:05, 2 hours 21 minutes ago BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Published on 08/03/2026 at 23:00, 12 hours 26 minutes ago Viemed Healthcare Announces Second Quarter 2026 Financial Results
Published on 08/01/2026 at 01:20, 3 days 10 hours ago Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 3 days 10 hours ago Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/04/2026 at 11:15, 11 minutes ago Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Published on 08/04/2026 at 11:05, 21 minutes ago Jo Malone London Launches Sea Salt & Bergamot, the 'scent of a new adventure'
Published on 08/04/2026 at 10:43, 43 minutes ago coinIX invests in Ampli - Infrastructure for AI-based asset management
Published on 08/04/2026 at 10:34, 52 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3H and Appendix 3Y
Published on 08/04/2026 at 10:15, 1 hour 11 minutes ago A Decade Beyond Boundaries: AKKO Celebrates 10th Anniversary with New European Products and IFA 2026 Showcase
Published on 08/04/2026 at 08:15, 3 hours 11 minutes ago Covivio - Conditions of availability of the 2026 Half-year report
Published on 08/03/2026 at 18:45, 16 hours 41 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 17:45, 17 hours 41 minutes ago Monthly disclosure of the total number of shares and voting rights - July 2026
